FDA recalls Medtronic biopsy kits. Medtronic stock sits 7.04 percent below its high

Published on 10/21/2026 at 10:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

FDA recall covers 3,746 kits on October 17, 2026. Medtronic stock costs EUR 84.36 on October 21, 2026, 7.04 percent below its high.

Recall and portfolio changes

The FDA recall covers 3,746 biopsy kits on October 17, 2026.
First-quarter fiscal 2027 revenue reached USD 9.76 billion, up 13.70 percent year over year.
Medtronic stock trades at EUR 84.36 at 10:33 a.m. CEST at Lang & Schwarz on October 21, 2026.
Medtronic's market capitalization stood at USD 121.0 billion as of October 20, 2026.

Isometrische 3D-Grafik der medizintechnischen Wertschöpfungskette von Rohstoff bis Klinik — Medtronic plc (ISIN IE00BTN1Y115) isometrische Grafik visualisiert Wertschöpfungskette von Rohstoff bis Krankenhaus schematisch, Illustration mit AI erstellt.

Medtronic plc (ISIN IE00BTN1Y115) was trading at EUR 84.36 at Lang & Schwarz on October 21, 2026, at 10:33 a.m. CEST, 7.04 percent below its 52-week high of EUR 90.75. The FDA recall of 3,746 biopsy kits is the latest dated company-specific development, according to Boerse Express on October 17, 2026.

FDA recall covers 3,746 kits

The Class II recall concerns biopsy needle kits made by Medtronic Navigation, Inc. Material deviations in reflective components can interfere with optical tracking during image-guided procedures. The affected products are used with surgical navigation systems, making the recall relevant to Medtronic's medical-surgical portfolio.

The recall report also said Medtronic stock closed at EUR 84.34 on October 16, 2026, after a 1.40 percent decline. That dated move was linked in the report to broad technology-sector selling rather than a company-specific trading trigger.

What changed in the portfolio?

Medtronic completed the separation of MiniMed in October. The company exchanged 252,813,348 MiniMed shares for 55,032,401 Medtronic ordinary shares, according to Boerse Express. The transaction leaves Medtronic with a different revenue mix and a stronger emphasis on cardiovascular, surgical and neuroscience technologies.

Three dated operating milestones

On October 1, 2026, Medtronic announced regulatory approvals for the Altaviva and Symplicity Spyral systems, as listed in the company's Medtronic release archive. On October 7, 2026, it announced a final exchange ratio of 4.5939 for the MiniMed split-off in the same archive. On October 17, 2026, the FDA recall covered 3,746 biopsy kits, according to Boerse Express.

Medtronic's first-quarter fiscal 2027 revenue was USD 9.76 billion, up 13.70 percent from the prior-year quarter, while adjusted earnings per share reached USD 1.45 against a USD 1.39 consensus estimate, according to MarketBeat on October 19, 2026.

Stock remains below its yearly high

Medtronic's primary listing is on the NYSE, where the stock was last quoted at USD 94.63 on October 20, 2026. Its market capitalization was USD 121.0 billion, and the 52-week range was USD 73.31 to USD 106.33. The recall adds a product-quality issue to a portfolio transition that is otherwise being measured against stronger reported revenue growth.

The stock was trading at EUR 84.36 at Lang & Schwarz on October 21, 2026, at 10:33 a.m. CEST, 7.04 percent below its 52-week high of EUR 90.75. The further course of trading is shown by the continuously updated real-time quote of Medtronic stock.